Mark Goldsmith

Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY.

Cogentus Pharmaceuticals, Inc. develops pharmaceutical products. Its investors include The Keffi Group, Prospect Venture Partners, Ridgeback Capital, Apothecary Capital, and Pinnacle Ventures. The company was founded by Mark A. Goldsmith in 2006 and is headquartered in Menlo Park, CA

Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA.

Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland.

Prospect Venture Partners (Prospect Venture Partners) is a venture capital firm founded in 1997 by David Schnell. The firm is headquartered in Palo Alto, California.

The J. David Gladstone Institutes operates as an independent state-of-the-art biomedical research institution. The company was founded in 1979 and is headquartered in San Francisco, CA.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.